Klivira
Request demo

Streamlining Trelegy Prior Authorization for Rheumatology Practices

Managing Trelegy prior authorization for rheumatology patients presents unique administrative demands, requiring efficient processes to ensure timely access to necessary therapies.

Rheumatology practices frequently navigate complex prior authorization landscapes, particularly for advanced therapies. While Trelegy is a high-volume PA target, the broader rheumatology specialty faces distinct challenges with biologics and targeted synthetic DMARDs, demanding robust automation to mitigate delays and denials.

The Administrative Burden of High-Volume Prior Authorizations

Trelegy is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. Managing the administrative overhead for such frequently prescribed medications, alongside a diverse portfolio of other drugs, requires a streamlined approach to avoid bottlenecks and ensure consistent patient care.

Navigating Prior Authorization in Rheumatology

Rheumatology is among the highest PA-burden specialties, primarily due to the chronic nature of autoimmune diseases and the high cost of advanced agents. Prior authorizations concentrate heavily in biologic and targeted therapies, including TNF-alpha inhibitors, non-TNF biologics, and JAK inhibitors, which are central to managing conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Key Documentation Requirements for Rheumatology PAs

  • Diagnosis documentation, including ICD-10 codes and disease-specific criteria (e.g., 2010 ACR/EULAR criteria for RA, CASPAR criteria for PsA).
  • Disease activity assessment scores (e.g., DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE).
  • Documentation of prior conventional DMARD trial and response (e.g., methotrexate trial) or contraindication, per indication.
  • Evidence of step therapy compliance, often requiring failure of specific TNF inhibitors before non-TNF biologics or JAK inhibitors.
  • Completion of pre-initiation screenings, such as TB screening (PPD or IGRA), hepatitis B/C screening, and updated immunization status.

Common Prior Authorization Denial Reasons in Rheumatology

  • Failure to document specific prior agent trial in the required step therapy sequence.
  • Denial of brand TNF inhibitor when biosimilar substitution is mandated by the payer.
  • Missing or incomplete disease activity scores (e.g., DAS28, CDAI, PASI).
  • Insufficient duration of conventional DMARD trial, not meeting payer-required timelines.
  • Gaps in screening documentation, such as incomplete TB, hepatitis, or immunization records.
  • Request for off-indication use of a biologic without supporting payer-specific policy.

Klivira's Solution for Complex Prior Authorizations

Klivira automates prior authorization workflows by integrating directly with EMRs and payer portals, streamlining submissions for high-volume medications and complex specialty drugs. Our platform is designed to reduce manual effort, accelerate approvals, and decrease denial rates across a wide range of therapies, including those frequently encountered in rheumatology.

Optimizing Rheumatology Workflows with Klivira

Klivira's platform addresses the specific workflow constraints of rheumatology. This includes managing periodic re-authorization for chronic biologic treatments, navigating variable biosimilar substitution policies, and handling the medical-vs-pharmacy benefit split for agents depending on administration mode and payer policy. Our ACR-guideline-aware policy logic supports accurate step therapy sequencing per indication.

Frequently asked questions

Why are prior authorizations for rheumatology medications often so complex?

Prior authorizations in rheumatology are complex due to the chronic nature of autoimmune diseases, the high cost of advanced biologic and targeted therapies, and stringent payer requirements for adherence to step therapy protocols and clinical guidelines like those from the ACR.

How does Klivira handle the variability in biosimilar substitution policies for rheumatology drugs?

Klivira's payer-policy logic incorporates specific per-payer mandates for biosimilar substitution. This guides staff on required sequences and facilitates appropriate routing decisions, ensuring compliance with diverse payer requirements for brand-to-biosimilar conversions.

Can Klivira assist with periodic re-authorizations common in chronic rheumatology treatments?

Yes, our platform supports continuous re-authorization workflows for chronic biologics and other long-term treatments. Klivira prompts for required documentation of disease response and activity scores at regular intervals, streamlining the re-authorization process.

What role does EMR integration play in streamlining prior authorizations for high-volume drugs?

EMR integration is crucial for high-volume prior authorizations like Trelegy. It allows Klivira to pull necessary clinical data directly from the patient record, pre-populating PA requests and significantly reducing manual data entry, which enhances efficiency and accuracy.

Does Klivira support both medical and pharmacy benefit prior authorizations for rheumatology treatments?

Yes, Klivira handles the medical-vs-pharmacy benefit split routing for the same agent, adapting to administration mode and payer policy to ensure correct submission. This is vital for rheumatology drugs that may be self-administered (pharmacy benefit) or provider-administered (medical benefit).

Related coverage

Other trelegy prior authorization by payer

Other trelegy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo